Document is current
Any future updates will be listed below
-
Authors
Fukumitsu, Hayato
Sakaguchi, Kazuhiko https://orcid.org/0000-0003-1577-2401
Nishisaka, Marika
Katsura, Yukari
Morita, Yasuko
Otowa-Suematsu, Natsu
Yamada, Tomoko
Yano, Yoshihiko
Takahashi, Michiko
Asahara, Shun-Ichiro
Ogawa, Wataru
-
Funding
Funding for this research was provided by:
Kobe University
- License Information
-
More Information
Article History
Received: 18 August 2025
Accepted: 24 December 2025
First Online: 21 January 2026
Declarations
:
: Author Ogawa has received scholarship donations from Sumitomo Pharma Co., Ltd.; research funding from Noster Inc., Boehringer Ingelheim Japan Ltd., Eli Lilly Japan K.K., Sumitomo Pharma Co., Ltd., and Novo Nordisk Pharma Ltd.; and honoraria for lectures from Sumitomo Pharma Co., Ltd., Abbott Japan LLC, Boehringer Ingelheim Japan Ltd., Novo Nordisk Pharma Ltd., and Eli Lilly Japan K.K. Author Sakaguchi has received research funding from Sumitomo Pharma Co., Ltd.; and honoraria for lectures or educational activities from Sumitomo Pharma Co., Ltd., Novartis Japan, Otsuka Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., and Sanofi K.K. Author Fukumitsu, Author Nishisaka, Author Katsura, Author Morita, Author Otowa-Suematsu, Author Yamada, Author Yano, Author Takahashi, and Author Asahara declare that they have no conflict of interest.
: This study protocol was approved by the Ethics Review Committee of Kobe University Hospital on April 26, 2024 (Approval No. B230230) and was conducted in accordance with the Declaration of Helsinki and its amendments.
: Written informed consent was obtained from all participants included in this study.
